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Abstract
Background: Hypertriglyceridemia may be associated with important complications. The aim of this study is to
estimate the magnitude of association and quality of supporting evidence linking hypertriglyceridemia to
cardiovascular events and pancreatitis.
Methods: We conducted a systematic review of multiple electronic bibliographic databases and subsequent meta-
analysis using a random effects model. Studies eligible for this review followed patients longitudinally and
evaluated quantitatively the association of fasting hypertriglyceridemia with the outcomes of interest. Reviewers
working independently and in duplicate reviewed studies and extracted data.
Results: 35 studies provided data sufficient for meta-analysis. The quality of these observational studies was
moderate to low with fair level of multivariable adjustments and adequate exposure and outcome ascertainment.
Fasting hypertriglyceridemia was significantly associated with cardiovascular death (odds ratios (OR) 1.80; 95%
confidence interval (CI) 1.31-2.49), cardiovascular events (OR, 1.37; 95% CI, 1.23-1.53), myocardial infarction (OR, 1.31;
95% CI, 1.15-1.49), and pancreatitis (OR, 3.96; 95% CI, 1.27-12.34, in one study only). The association with all-cause
mortality was not statistically significant.
Conclusions: The current evidence suggests that fasting hypertriglyceridemia is associated with increased risk of
cardiovascular death, MI, cardiovascular events, and possibly acute pancreatitis.
Précis: hypertriglyceridemia is associated with increased risk of cardiovascular death, MI, cardiovascular events, and
possibly acute pancreatitis
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Background
Hypertriglyceridemia is a manifestation of several com-
mon metabolic disorders in the western world. A recent
cross-sectional study found that over 33% of adults in the
United States had hypertriglyceridemia (serum triglycer-
ide levels over 150 mg/dl (1.7 mmol/L)) of whom over
50% had serum triglyceride levels exceeding 200 mg/dl
(2.2 mmol/L) [1].
The association of hypertriglyceridemia and clinically
important complications such as cardiovascular events
and acute pancreatitis has been suggested by several
studies. Previous epidemiologic studies demonstrated
increase in the risk of cardiovascular events although
there has always been significant confounding due to
varying levels of adjustments for traditional risk factors
and other lipid subfractions [2-4]. As for pancreatitis,
case series and uncontrolled studies reported that very
severely elevated triglyceride levels are associated with
lipemic serum, chylomicronemia syndrome, and
increased risk of pancreatitis [5-7]. Serum triglycerides
levels of 1000 mg/dl (11.3 mmol/L) and higher have been
observed in 12% to 38% of patients presenting with acute
pancreatitis [5]. However, the association with pancreati-
tis has not been evaluated in controlled studies or with
less severe hypertriglyceridemia.
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meta-analysis [2] was performed 6 years ago), we con-
ducted this systematic review and meta-analysis. Our
goal was to assess the magnitude of association and the
quality of supporting evidence linking hypertriglyceride-
mia with cardiovascular events, mortality and pancreati-
tis. We specifically aimed at comparing association
measures in studies with varying levels of adjustment for
cardiovascular risk factors and to search for controlled
studies evaluating the risk of pancreatitis.
Methods
This systematic review was conducted according to a
priori established protocol that was commissioned and
funded by the Endocrine Society and is reported according
to the PRISMA statement (Preferred Reporting Items for
Systematic Reviews and Meta-analyses) [8].
Eligibility criteria
Eligible studies were randomized and observational studies
that enrolled patients with untreated hypertriglyceridemia
and reported a relative association measure between fast-
ing serum triglycerides levels and the outcomes of interest:
all-cause mortality, cardiovascular death, cardiovascular
events and pancreatitis. We excluded uncontrolled studies
and studies of nonfasting hypertriglyceridemia.
Study identification and data extraction
An expert reference librarian (P.J.E) created and imple-
m e n t e dt h ee l e c t r o n i cs e a r c hs t r a t e g yw i t hi n p u tf r o m
study investigators (V.M.M. & M.H.M). We searched Ovid
MEDLINE, Ovid EMBASE, Web of Science and SCOPUS
through August of 2010. The detailed search strategy is
available in Additional file 1. We also sought recommen-
dations from content expert for potentially relevant studies
to be included in the screening process.
Reviewers working independently and in duplicate
assessed each abstract for eligibility. Disagreements yielded
an automatic inclusion into the following level of screen-
ing. Included studied were retrieved and full text screening
commenced in duplicate as well. Disagreements in this
level were resolved by discussion and consensus. Online
reference management system was used to conduct this
review and it reported a real-time chance-adjusted agree-
ment (kappa) statistic to evaluate the agreement among
reviewers. Kappa averaged 0.80. Two reviewers working
independently and in duplicate extracted baseline and out-
come data and assessed the quality of included study. A
third reviewer compared the reviewer’s data and resolved
inconsistencies by referring to the full text article.
Quality
Using the Newcastle-Ottawa scale, [9] reviewers assessed
the quality of included observational studies (and control
arms of RCT, considered as observational cohorts) by
determining outcome ascertainment, adjustment for con-
founders, proportion of patients lost to follow-up as well
as sample selection. We used the GRADE approach in
evaluating the evidence yielded from included studies
[10].
Statistical analysis
We pooled the relative association measures of relevant
complications from included studies and analyzed the data
using the random-effects model described by DerSimonian
and Laird [11]. Heterogeneity in results across studies was
measured using the I
2 statistic, which estimates the pro-
portion of variation in results across studies that is not
due to chance. An I
2 of 50% or more indicates large incon-
sistency between studies. Meta-analysis was completed
using Comprehensive Meta-analysis (CMA) version 2.2
(Biostat Inc., Englewood, NJ).
Subgroup analyses and publication bias
Ap r i o r ihypotheses were designed to explain between-
study inconsistencies in results. These analyses sought an
interaction with whether triglycerides levels were
adjusted for other lipid fractions or not; whether the
underlying metabolic disorder was diabetes vs. not; and
whether the association differed between men and
women. Publication bias was evaluated by assessing the
symmetry of funnel plots and using Egger’s regression
test. In this regression, the size of the treatment effect is
c a p t u r e db yt h es l o p eo ft h er e g r e s s i o nl i n ea n db i a si s
captured by the intercept [12].
Results
Search results and included studies
Electronic search yielded 760 potentially eligible stu-
dies. Following screening, 60 studies met inclusion cri-
teria, of which 35 reported data sufficient for meta-
analysis [Figure 1].
Methodological quality and risk of bias
Included studies had a fair methodological quality
(Table 2) with follow-up period reported by 85% of stu-
dies averaging 114 months; 58% of studies reported loss
to follow-up of participants that ranged 0% to 27%.
Adjustment for potential confounders was reported in
90% of studies and the outcome ascertainment method
was reported in all studies. Cohort selection was random
in 18% of the studies.
Meta-analysis
The total number of included studies was 35 enrolling
927,218 patients who suffered 132,460 deaths and
72,654 cardiac events; respectively. Hypertriglyceridemia
was significantly associated with cardiovascular death,
cardiovascular events, myocardial infarction, and pan-
creatitis; with odds ratios (95% confidence interval) of
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Page 2 of 181.80 (1.31-2.49), 1.37 (1.23-1.53), 1.31 (1.15-1.49) and
3.96 (1.27-12.34); respectively. There was nonsignificant
association with all-cause mortality (OR: 1.10; 95% CI:
0.90-1.36). Forest plots depicting the results of random
effects meta-analysis are presented in Figures 2, 3, 4 and 5.
It is worth noting that the association with acute pan-
creatitis was estimated by only one eligible study that
included 129 patients with severe hypertriglyceridemia
(119 with type IV phenotypes and 10 with type V pheno-
types according to Fredrickson’s classification) of whom
26 suffered acute pancreatitis [33]. In this study, subjects
in the third tertile of TG had a 4.0-fold increased risk
(95% confidence interval, 1.3-12.3) compared with the first
tertile and those diagnosed with dyslipidemia at a younger
age also had increased risk.
All analyses were associated with important heterogene-
ity (I
2 > 50%) that our planned subgroup analyses could
only partially explain (Table 3). The association of hyper-
triglyceridemia with mortality and cardiovascular mortality
seemed to be stronger in women. These findings are con-
sistent with a previous meta-analysis published in 1996.
Hokanson and Austin estimated adjusted relative risks for
incident cardiovascular events of 1.14 (95% Cl 1.05-1.28)
in men and 1.37 (95% Cl 1.13-1.66) in women. The asso-
ciation with cardiovascular events was somewhat stronger
in patients with diabetes although this effect was not sta-
tistically significant. Hence, there were no other significant
subgroup interactions to explain heterogeneity (based on
the level of adjustment for lipids subfractions, sex or the
presence of diabetes).
There was no evidence of publication bias (P value for
Eggers test > 0.05 for all outcomes) although these ana-
lyses were underpowered to detect this problem and the
presence of heterogeneity further limits the ability to
detect publication bias.
Discussion
We conducted a systematic review and meta-analysis
and documented an association between fasting hyper-
triglyceridemia and the risk of several cardiovascular
adverse events and with pancreatitis.
Limitations, strengths and comparison with other reports
The main limitation of association studies is the observa-
tional nature of the existing evidence. Therefore, con-
founders (particularly, baseline risk of patients for
developing cardiovascular disease and the effect of other
lipid subfractions abnormalities) threaten the validity of
results. In meta-analyses of observational studies, the
ability to adjust for confounding is limited by the level of
adjustment conducted in the original studies. We
attempted to evaluate confounding by conducting sub-
group analysis; however, this analysis was underpowered.
Other limitations pertain to heterogeneity of the meta-
analytic estimates, publication bias (which remains likely
in the context of observational studies that do not require
prospective registration) and reporting bias (which is also
likely considering that several studies met the eligibility
criteria for this review but did not report the outcomes of
interest) [48]. It was unclear in most studies if enrolled
patients did not have some of the outcomes pre-existent
at baseline and it was also unclear if patients were treated
with drugs that can affect TG level (both of these ele-
ments lower the confidence in the observed associations).
We only found one controlled study that evaluated the
association with acute pancreatitis.
Potentially relevant studies identified by search 
(n=765) 
Articles selected for full text retrieval (n=186) 
Excluded after abstract screening (n=579) 
Studies that fulfilled inclusion criteria (n=60) 
Excluded after full-text screening: (n=126) 
•Studies with no original data (n=8) 
•Ineligible populations (n=16) 
•No association of varying TG levels 
(n=46) 
•Irrelevant outcomes (n=41) 
•Unobtainable full text (n=15) 
Studies included in review (35) 
Studies with insufficient data for analysis 
(n=25) 
Figure 1 Study selection process.
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Study Label Design Objective of Study Population Age
(mean)
Sample
Size
Length
of
Follow-
up
Definition of CV
events
Acarturk,
2004[13]
Prospective
cohort
to investigate the relation
between age and gender
differences in plasma TG and
CAD in patients with
angiographically proven
CAD
patients
admitted for
diagnostic
coronary
angiography
due to chest
pain
54.9
+/-10.26
937 NR Coronary artery
disease
Bansal, 2007
[14]
Prospective
cohort
To determine the association
of triglyceride levels (fasting
vs nonfasting) and risk of
future cardiovascular events.
healthy women 54.2 +/-
7.06
26,509 136.8
Months
(median)
composite of
confirmed nonfatal
MI, nonfatal ischemic
stroke, coronary
revascularization, or
death due to
cardiovascular causes
Barrett-
Connor, 1987
[15]
Prospective
cohort
To examine the independent
effect of triglyceride on the
prediction of cardiovascular disease
after the effects of cholesterol and
other heart
disease risk factors have been
accounted for
healthy fasting
men without
known CVD
57.7 1,589 144
months
N/A
Bass, 1993
[16]
Prospective
cohort
To further explore the relationships
between lipid
and lipoprotein levels and
other conventional CVD risk factors
and CVD death on women
women 30
years of age
and older
58.2 +/-
5.5
1,405 Mean
168
months
N/A
Bonaventure,
2010[17]
Prospective
cohort
To find the association
pattern between serum TG
and incident intracerebral
hemorrhage as compared
with coronary events and ischemic
stroke
Population-
based, elderly
participants
free from
institutionalization
were recruited
from the electoral
rolls of three
French cities
74.03
years
8,393 mean of
5 years
MI, hospitalized
angina pectoris, acute
coronary
syndrome, coronary
endovascular
dilatation, coronary
bypass, or death due to
a coronary event
Carlson, 1988
[18]
RCT To obtain a pronounced
serum lipid lowering by combined
use of clofibrate
and nicotinic acid in an effort
to reduce the risk of IHD
Survivors of
MI < 70 years
of age
58.9 + -0.4
males and
62.5 + -0.9
females
Control
group (n
= 276)
60
months
N/A
Chan, 2005
[19]
Prospective
cohort
To examine the lipid profiles
in Chinese type 2 diabetic patients
and their relationship with
anthropometric parameters,
glycemic control and cardiovascular
mortality.
Chinese
patients with
type 2 DM
54.0 +/-
14.0
517 Mean
55.2
+/-10.8
months
N/A
Chester, 1995
[20]
Prospective
cohort
To determine the standard clinical
or angiographic variables or both
present at initial angiography
associated with the development of
adverse coronary events in patients
awaiting routine
PTCA
Patients
awaiting
routine
percutaneous
transluminal
coronary
angioplasty
(PTCA)
57 215 Median
8
months
fatal or non-fatal MI,
unstable angina or
angiographic new total
coronary occlusion
Czernichow,
2007[21]
Prospective
cohort
To investigated the
relationship of baseline
‘hypertriglyceridemic waist’ (HTGW)
status with CVD
risk in middle-aged French
men
middle-aged
French men,
included
diabetics
51.9 +/-
4.7
3,430 90
months
new-onset angina,
fatal and non-fatal MI or
stroke, transient ischemic
attack,
sudden death or
intermittent claudication
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Drexel, 2005
[22]
Prospective
cohort
To evaluate the
atherogenicity of lipids in coronary
patients with
normal fasting glucose
(NFG), impaired fasting glucose
(IFG), and type 2
DM
Caucasian
patients who
were referred
to coronary
angiography
62.4 +/-
10.6
750 27.6 +/-
4.8
months
N/A
Eberly, 2003
[23]
Prospective
cohort
To determine whether HTG
is an independent risk factor
for coronary heart disease (CHD),
and whether fasting
and nonfasting triglyceride (TG)
levels are equally predictive
men at increased
risk but without
clinical
evidence of
definite CHD
at baseline
46.3 2809 304.8
months
either a clinical MI or
a significant serial
electrocardiogram
change indicative of
MI
Egger, 1999
[24]
Prospective
cohort
To assess the influence of
differential precision in the
measurement of the
correlated variables total cholesterol
and HDL cholesterol on estimates
of
risk of IHD associated with
TG levels
Middle aged
men living in
the town of
Caerphilly,
South Wales,
UK
52.1 +/-
4.48
2,512 5 and
10 years
after
baseline
death from ischemic
heart disease, clinical
non-fatal MI,
electrocardiographic
MI
Ellingsen,
2003[25]
Prospective
cohort
to examine the effect of
group assignment on IHD mortality
in subjects with normal or high
fasting TG
healthy men
who had an
elevated serum
total
cholesterol
concentration
or coronary
risk score
46 +/-3 1232 276
months
N/A
Gaziano,
1997[26]
Case
controlled
study
To examine the interrelationships of
the
fasting TG level other lipid
parameters and nonlipid risk factors
with risk of MI.
Patients -
coronary care
and other
intensive care
units patients
(no history of
MI and angina
pectoris) with
whom
symptoms of
MI had begun
24 h of
admission,
control -
residents of
home towns.
57.7 +/-
9.65
680 NR N/A
Goldberg,
2009[27]
Prospective/
case
controlled
To ascertain coronary artery disease
outcomes and
predictive factors in patients with
SLE and matched
healthy controls
prospectively
Patients with
systemic lupus
erythematosus
(SLE) and
matched
healthy
controls
SLE cases
44.2
+/-12.2,
controls
44.5 +/-
4.4
237
controls
and 241
SLE
cases
86.4
months
Defined as the
occurrence of MI and/or
angina pectoris due to
atherosclerosis.
Habib, 2006
[28]
Prospective
cohort
To evaluate the association of
serum TC and TG with
clinical outcomes in chronic
peritoneal dialysis (PD)
patients.
Patients on
chronic
peritoneal
dialysis; only
in end-stage
renal disease
(ESRD) or
patients those
very ill
patients who
died rapidly
due to unrelated
conditions.
57.2 +/
15.3
1,053 23 +/-
14
months
N/A
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Haim, 1999
[29]
Prospective
cohort
To investigate the association
between elevated blood triglyceride
levels and subsequent mortality risk
in patients with established
coronary heart disease
(CHD)
patients with a
diagnosis of CHD
59.76 +/-
6.96
11,546 61.2
months
N/A
Hoogeveen,
2001[30]
Case
controlled
study
To determine the effect of
immigration to the USA ion plasma
levels of lipoprotein a and other
independent risk factors for CHD in
Asian Indians
Asian Indians
and Asian
Indians living
in the USA
with and
without CHD
44.2 +/-
12.79
309 NR Coronary heart disease -
incidents not specifically
defined
Jonsdottir,
2002[31]
Prospective
cohort
To examine the relationship
between the relative risk of baseline
variables and
verified MI or coronary death
in individuals with no prior history
of MI
male and
female from
Reykjavik and
adjusted
communities
52.7 +/-
8.71
18,569 Mean
208.8
months
N/A
Lamarche,
1995[32]
Prospective
cohort
To confirm the importance of both
elevated plasma cholesterol and
decreased
high density lipoprotein cholesterol
levels as risk
factors for ischemic heart disease
men without
ischemic heart
disease
57.5 2,103 60
months
Effort angina pectoris,
coronary
insufficiency, nonfatal MI,
and coronary
death
Lloret Linares,
2008[33]
Retrospective
cohort
to assess retrospectively the
prevalence and the predictive
factors of acute pancreatitis (AP)
Patients
referred by
their general
practitioner or
general
hospital for
very high TG
levels.
47 +/-
10.7
129 NR N/A
Lu, 2003[34] Prospective
cohort
To determine whether non-
HDL cholesterol, a measure
of total cholesterol minus
HDL cholesterol, is a
predictor of CVD in patients with
DM
American
Indians with
DM
57.28 +/-
8
2,108 108
months
Coronary heart
disease,
MI, stroke, and other
CVD
Malone, 2009
[35]
Prospective
cohort
This study evaluated
cardiometabolic risk factors
and their relationship to prevalent
diagnosis of acute
MI (AMI) and stroke.
People
continuously
receiving
health
insurance
benefits during
study
56.8 +/-
0.03
170,648 24
months
N/A
Mazza, 2005
[36]
Prospective
cohort
To evaluate whether TG level
is a risk factor for CHD in elderly
people from general population,
and to look for interactions
between TG and other risk factors.
elderly people
from general
population
CHD in elderly
people from
general
population
73.8 +/- 5 3,257 144
months
N/A
Mora, 2008
[37]
Prospective
cohort
To evaluate levels of lipids
and apolipoproteins after a typical
meal and to determine whether
fasting compared
with non-fasting alters the
association of these lipids
and apolipoproteins with incident
CVD.
Healthy
women, aged
> = 45 years,
who were free
of self-
reported CVD
or cancer at
study entry and
with follow-up for
incident CVD.
54.7 26,330 136.8
months
Nonfatal MI,
percutaneous
coronary
intervention,
coronary artery
bypass grafting, nonfatal
stroke,
or
cardiovascular
death
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Noda, 2010
[38]
Case
controlled
study
To examine the prediction of
coronary risk factors and evaluation
of the predictive value for MI
among Japanese middle-aged male
workers.
Japanese male
workers
cases 50.4
+ -5.3,
controls
50.4 + -5.5
years
cases
204 and
controls
408
36
months
N/A
Rubins, 1999
[39]
RCT To analyze the role of raising HDL
cholesterol level and lowering
triglyceride levels
to reduce the rate of coronary
events in patients with
existing cardiovascular
disease
men with
coronary heart
disease with
absence of
serious
coexisting
conditions
64 + -7 1267
(placebo)
61.2
months
combined incidence of
nonfatal MI or death
from coronary heart
disease
Samuelsson,
1994[40]
Prospective
cohort
To analyze the importance of DM
and HTG as potential
risk factors for CHD in
middle-aged, treated hypertensive
men
middle aged
treated
hypertensive
men
52 +/- 2.3 686 180
months
Non-fatal MI, a fatal MI, a
death certificate
statement of coronary
atherosclerosis as the
cause of death
Schupf, 2005
[41]
Prospective
cohort
To investigate the
relationship between plasma lipids
and risk of death from
all causes in non demented elderly
Community-
based sample
of Medicare
recipients
without
dementia
76.1 2,277 Mean 36
+/- 30
months
N/A
Sprecher,
2000[42]
Prospective
cohort
To evaluate the predictive
value of serum triglyceride levels on
mortality in post coronary artery
bypass graft(CABG) diabetic
patients with subsequent analysis
by sex
Diabetic post
CABG patients
at a large
metropolitan
hospital
63 +/- 9 1,172 84
months
N/A
Tanko, 2005
[43]
Prospective
cohort
To investigate the relative utility of
enlarged waist combined with
elevated TG (EWET) compared with
the National Cholesterol
Education Program (MS-NCEP)
criteria in estimating future risk of
all-cause and cardiovascular
mortality
Postmenopausal
women
60.4 +/-
7.1
557 8.5 +/-
0.3 years
N/A
Tsai, 2008[44] Retrospective
cohort
To assess the effect of a
single and a combination of “pre-
disease” risk factors of metabolic
syndrome on the overall and
cardiac mortality.
civil servants
and teachers
40 years and
older
52.4 + -
8.0
35,259 median
follow-
up of 15
years
N/A
Upmeier,
2009[45]
Prospective
cohort
To determine whether high levels
of serum total
cholesterol and low levels of HDL
are related to increased mortality in
elderly
Home
dwelling older
adults residents in
Finland
70 years 877 144
months
N/A
Valdivielso,
2009[46]
Prospective
cohort
To study the prevalence, risk factors
and vascular disease associated
with moderate and sever HTG in an
active
working population
Active
working
population of
Spain
36 ± 10
years
594,701 NR documented prior
medical
diagnosis of heart
disease, cerebrovascular
disease or peripheral
arterial disease
Wier, 2003
[47]
Prospective
cohort
To investigate the
relationship between triglyceride
and stroke
outcome
nondiabetic
patients
presenting to
acute stroke
unit
Median
70 years
1310 mean
1195
days
N/A
UC/NR: unclear, not reported; TG: Triglycerides; HTG, hypertriglyceridemia; MI, myocardial infarction; DM, diabetes, BP, blood pressure, HTN, hypertension
Triglycerides Conversion: from mg/dL to mmol/L: multiply by (x) 0.01129; from mmol/L to mg/dL: multiply by (x) 88.6
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Study Label Cohort Selection (sampling) Outcome ascertainment* Adjustments for variables % lost
to
follow-
up
Definition of hypertriglyceridemia
Acarturk,
2004[13]
not random; all patients
admitted for diagnostic
coronary angiography
chart review, angiography
results
NR NR TG value in the blood was used
as a continuous number
(variable). OR expresses
increased risk per unit of serum
TG level
Bansal, 2007
[14]
derived from women health study, previously
completed randomized controlled trial of
aspirin and vitamin E
chart review, events
adjudicated by
an end point committee
adjusted for treatment
assignment to ASA,
vitamin E, beta
carotene, age, BP,
smoking status, and use
of hormone therapy,
levels of total
cholesterol and HDL-C,
history of DM, BMI,
high-sensitivity C-
reactive protein
0 TG value in the blood was used
as a continuous number
(variable). OR expresses increased risk per
unit of serum TG level
Barrett-
Connor, 1987
[15]
random sample chart review, ICD or billing
codes,
death certificates
adjust by TG level, age,
BP, BMI, smoking
habit, DM, family
history of heart attack
0.5% Compared normal to “borderline HTG”,
defined as TG between
240-500 mg/dL (2.7-5.65
mmol/L)
Bass, 1993
[16]
subset of female participants
in the Lipid Research Clinics’ Follow-up Study
chart review, annual checkups Adjusted for age, HTN,
DM, smoking, history
of heart disease and
estrogen use
NR Compared TG < 200 mg/dL
(< 2.25 mmol/L) to elevated 200
to 399 mg/dL (2.25 to 4.49
mmol/L) and high > 400 mg/dL (> 4.50
mmol/L)
Bonaventure,
2010[17]
not random and not consecutive: recruited
from electoral rolls
Death certificates and autopsy
reports, ascertained the same
way
in cases and controls
medical history of MI,
stroke, or peripheral
arterial disease, as well
as smoking and alcohol consumption status
(never, former, current),
excess weight, elevated
BP, DM, apolipoprotein
E (APOE) genotype,
low-dose aspirin intake, and lipid-lowering
treatment
NR They compared tertiles or
quintiles: TG < 83.4 mg/dL
(< 0.94), 84.2-117.8 mg/L (0.95-1.33), and >
118.7 mg/dL (1.34 mmol/L)
Carlson, 1988
[18]
consecutive sample (all patients presenting with
HTG)
chart review, ascertained the
same
way in cases and controls,
done
without knowledge of patients’
TG
level
NR 13.4% 3 groups according to TG levels. Low =
TG < 132.9 mg/dL (1.5 mmol/L),
intermediate = TG
132.9-177.2 mg/dL (1.5-2.0 mmol/L), high
= TG > 177.2 (2.0 mmol/L).
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Chan, 2005
[19]
not random;
consecutive patients with type 2 DM, not HPTG
chart review, death registry Adjusted for sex
and age. stepwise linear regression with
BMI,
WC, HbA1c, FPG and
HOMA as independent
variables and lipid
profile as dependent
variable
0 Unclear
Chester, 1995
[20]
consecutive sample (all men presenting with
HTG and are awaiting routine angioplasty)
chart review,
done without knowledge of
patients’ TG level
The potential predictor
variables-that is, risk
factors assessed at
baseline angiography,
for adverse events were
analyzed using the
multiple logistic
regression models.
2 TG value in the blood was used
as a continuous number
(variable). Here OR expresses increased risk
per unit of serum
TG level: mmol/L
Czernichow,
2007[21]
consecutive sample self report, chart review, ICD or
billing codes, ascertained
differently: self report in all
patients, however if a CVD
event
was reported – chart review
and
ICD billing codes were
reviewed
for those individuals only
Age NR Age-adjusted relative risk
correlate to one standard
deviation increase in TG levels
Drexel, 2005
[22]
consecutive sample follow up investigation after 2.3
years, Time and causes of
death
were obtained from national
surveys, hospital records
age, sex, and use of
lipid-lowering
medication
0 Unclear
Eberly, 2003
[23]
not random; likely consecutive sample: 2863
men with both nonfasting and fasting TG levels
measured at screens 1 and 2
self report, chart review, ICD or
billing codes, death certificates
age, lipids subfractions,
glucose level, BP,
cigarettes smoked per
day, alcohol use, BMI
and race
0 TG value in the blood was used
as a continuous number
(variable). Here OR expresses increased risk
per unit of serum
TG level: mg/dL
Egger, 1999
[24]
not random; likely consecutive sample:
Participants of the Caerphilly Heart Disease
Study
self report, chart review, ICD or
billing codes
age, all three lipid
factors, laboratory error
and within person
variation, blood
glucose and diastolic
BP, BMI, smoking and
markers for pre-existent
disease
12.5 TG value in the blood was used
as a continuous number
(variable). Here OR expresses increased risk
per unit of serum
TG level: mmol/L
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8Table 2 Quality of Included Studies (Continued)
Ellingsen,
2003[25]
not random; likely
consecutive sample: 1232
healthy men with elevated cholesterol or
coronary risk
score included in the study
from a pool of 16202
screened men
chart review, ICD or billing
codes, ascertained the same
way in cases
and controls
adjusted for age, BMI,
cigarette smoking, total cholesterol,
triacylglycerol, glucose,
BP, dietary score,
alcohol intake, and
activity level
0 TG value in the blood was used
as a continuous number
(variable). Here OR expresses increased risk
per unit of serum
TG level: high TG > or = 178.1 mg/dL
(2.01 mmol/L)
Gaziano,
1997[26]
not random, likely
consecutive sample:
Men/women < 76 yrs. age
with no prior history of CAD discharged from
one of 6
Boston area hospitals with the diagnosis of
confirmed MI
chart review, medical exam/lab
analysis,
ascertained differently: cases
were interviewed 8 weeks after
MI
Adjusted for age, sex,
history of HTN, history
of DM, body mass
index, type A
personality, family
history of previous MI,
alcohol consumption,
physical activity,
smoking, caloric intake
12 they compared quintiles, highest
compared to lowest
Goldberg,
2009[27]
consecutive sample (all
patients presenting with HTG)
chart review, telephone calls,
ascertained the same way in
cases
and controls
A time-to-event
regression model was
performed to establish
the role of baseline lipid subfractions, other
metabolic risk factors,
lifestyle variables, and demographic
characteristics in
relation to the development
of CAD.
3.8 high triglyceride level > = 248.1 mg/dL
(2.8 mmol/L)
Habib, 2006
[28]
Data from the United States Renal Data System
database collected during the
prospective Dialysis
Morbidity and Mortality
Study Wave 2 study
chart review age, gender, race,
weight, height, primary
cause of ESRD,
hemoglobin, serum
albumin, serum calcium phosphate product,
serum bicarbonate,
residual kidney
creatinine clearance, PD parameters
(dialysate
effluent volume,
dialysis creatinine
clearance, D/P creatinine ratio after a 4 h
dwell), use of lipid-modifying medications
and comorbidity characteristics
0 TG value in the blood was used
as a continuous number
(variable). Here OR expresses increased risk
per unit of serum
TG level: HR is using a
reference of TG levels 200-300
mg/dl (2.2-3.4 mmol/L)
Haim, 1999
[29]
not random; likely
consecutive sample
chart review, ICD or billing
codes
age, previous MI, DM,
NYHA class, HTN,
LDL cholesterol,
glucose, chronic
obstructive pulmonary
disease, peripheral
vascular disease, stroke,
angina pectoris,
smoking, and lipids
0.37 TG value in the blood was used
as a continuous number
(variable). Here OR expresses increased risk
per unit of serum
TG level: mg/dL
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8Table 2 Quality of Included Studies (Continued)
Hoogeveen,
2001[30]
Random sample chart review, clinical exam and
investigations,
ascertained the same way in
cases
and controls
Logistic regression
applied but no specific adjustments are
mentioned
12 TG value in the blood was used
as a continuous number
(variable). Here OR expresses increased risk
per unit of serum
TG level: 10 mg/dL (0.11 mmol/L)
Jonsdottir,
2002[31]
not random; likely
consecutive: subjects of the Reykjavik Study
self report, chart review, ICD or
billing codes
age, high-density lipoprotein cholesterol,
total/low-density lipoprotein cholesterol,
smoking, body mass index and BP
0.6 TG value in the blood was used
as a continuous number
(variable). Here OR expresses increased risk
per unit of serum
TG level: mmol/L
Lamarche,
1995[32]
random sample chart review, Examination/EKG/
death certificate
Adjusted for age,
systolic BP, DM,
alcohol consumption,
and tobacco use
27 TG value in the blood was used
as a continuous number
(variable). Here OR expresses increased risk
per unit of serum
TG level: TG > 203.8 mg/dL (2.3 mmol/L)
Lloret Linares,
2008[33]
not random and not
consecutive: Patients referred
by their general practitioner
or general hospital for very
high TG levels to
Endocrinology Dept. between 2000 and 2005
self report, chart review Adjusted for age at hospitalization NR TG: lowest 95.1-180 mg/dL
(1.1-2.0 mmol/L) vs. highest
360-1505 gm/dL (4.1-17
mmol/L).
Lu, 2003[34] not random; likely
consecutive: cohort chosen
from the strong heart study to include only
DM, no baseline CVD
through death certificates and
tribal
and Indian Health Service
hospital records and by direct
contact of
study personnel with the study
participants and their families
Adjusted for age, BMI,
smoking status, study
center, systolic BP,
HbA1c, fibrinogen,
insulin, and ratio of
albumin to creatinine
0 They compared tertiles or
quintiles: TG: lower < 111; 111-
175; higher > 175 mg/dL
(lower < 1.2; 1.2-2.0; higher > 2.0 mmol/L)
Malone, 2009
[35]
Not random; likely
consecutive: Retrospective
data from 3 integrated health-care systems that
systematically collect
and store detailed patient-level data.
Chart review, ICD or billing
codes
Adjusted for age, sex,
smoking status and site
N/A lower/normal TG - 80.0 mg/dl
(0.9 mmol/L); higher TG - TG = 217.4 mg/
dl (2.4 mmol/L)
Mazza, 2005
[36]
random sample chart review, ICD or billing
codes, through the Register
Office, general practitioners
Gender, age, DM,
obesity, lipids
subfractions, serum uric
acid, BP, smoking,
alcohol and proteinuria
0 They compared tertiles or
quintiles: TG: First (low) < 97.5 mg/dL
(1.01 mmol/L); Fifth (high) > = 156.8 mg/
dL (1.77 mmol/L)
Mora, 2008
[37]
Random sample enrolled in
the Women’s Health Study
Follow-up questionnaires every
6-
12 months
Adjusted for age,
randomized treatment assignment, smoking
status, menopausal
status, postmenopausal
hormone use, BP, DM,
and BMI
NR They compared tertiles or
quintiles: TG: First (low) < 89.5 mg/dL
(1.01 mmol/L); Fifth (high) > = 180.7 mg/
dL (2.04 mmol/L)
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8Table 2 Quality of Included Studies (Continued)
Noda, 2010
[38]
not random and not
consecutive: death related to a MI defined a
case, then 2 controls were selected
randomly matched by age
Death registration from 1997-
2000,
done without knowledge of
patients’ TG level,
ascertained the same way in
cases
and controls
Adjusted for age and 6
risk factors for MI
NR TG value in the blood was used
as a continuous number
(variable). Here OR expresses increased risk
per unit of serum TG level: High TG > =
150 mg/dL (1.7 mmoml/L)
Rubins, 1999
[39]
not random and not
consecutive: to obtain
population with appropriate
lipid levels, a multi stage screening method
that
included two lipid profiles obtained one week
apart
chart review, clinical and
radiologic
data, ascertained the same way
in
cases and controls
Adjustment for baseline
variables in the Cox
models had a trivial
effect on the estimates
of the hazard ratios
2.3% Two groups: TG < 150 mg/dl (1.7 mmol/L)
and TG > 150 mg/dl (1.7 mmol/L)
Samuelsson,
1994[40]
random sample chart review traditional risk factors,
end-organ damage
status
NR TG value in the blood was used
as a continuous number
(variable). Here OR expresses increased risk
per unit of serum
TG level: RR reported for every
88.6 mg/dL (1 mmol/L) increase
in TG level
Schupf, 2005
[41]
random sample self report, chart review,
interviewing relatives
Adjusted for age, sex,
ethnicity, and level of
education, for BMI or
APOE; a history of
HTN, DM, heart
disease, stroke, or
cancer; or current
smoking
0 They compared tertiles or
quintiles: Lowest - < = 98.9 mg/dl
(1.1 mmol/L), highest
- > 191.2 mg/dl (2.1 mmol/L); RR
compared the lowest quartile to
the highest quartile.
Sprecher,
2000[42]
not random; likely
consecutive: diabetic patients undergoing
primary isolated CABG between 1982 and
1992 at Cleveland Clinic
chart review, clinical exam, labs
and CVIR (Cardiovascular
Information Registry)
age, sex, left ventricular
function, coronary
anatomy, history of
HTN, BMI, and total
cholesterol
highest quartile compared to
lower three quartiles (normal)
Tanko, 2005
[43]
not random and not
consecutive:
recruited via a questionnaire surveys
self report, chart review: Central
Registry of the Danish Ministry
of
Health
Adjusted for age,
smoking, and LDL-C),
waist circumference
NR TG value in the blood was used
as a continuous number
(variable). Here OR expresses increased risk
per unit of serum
TG level: presented as 2 cutoffs - > 128.5
mg/dL (1.45 mmol/L) - > 149.7 mg/dL
(1.69 mmol/L)
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8Table 2 Quality of Included Studies (Continued)
Tsai, 2008[44] not random; likely
consecutive:
civil servants and teachers
who took the annual physical examination at
the Taipei Outpatient Center
chart review, annual exam,
national
death files
Adjusted for age,
gender, fasting glucose,
BP, BMI, smoking
NR They compared tertiles or
quintiles: TG
normal < 150 mg/dL (1.7
mmol/L, abnormal 150 mg/dL
(1.7 mmol/L)-199 mg/dL (2.2 mmol/L),
and high abnormal
> 200 mg/dL (2.25 mmol/L)
Upmeier,
2009[45]
not random and not
consecutive:
mailed invitation to
participate to all residents of Turku born in
1920
Self report, chart review,
ICD or billing codes
Adjusted for gender,
body mass index,
smoking and any history
of angina pectoris,
stroke, DM, and HTN
NR They compared TG level
quartiles, highest to lowest
Valdivielso,
2009[46]
not random; likely consecutive Chart review and self report age, sex, smoking,
HTN, DM, and lipids
fractions
NR Categorized as normal when TG
was < 150 mg/dL (< 1.69
mmol/L); the remainder were considered
to be HTG
Wier, 2003
[47]
not random; likely
consecutive
chart review,
done without knowledge of
patients’ TG level
age, time of resolution
of symptoms, smoking,
BP, presence of atrial
fibrillation and
hyperglycemia
0 They compared tertiles or
quintiles: TG, mmol/l: < = 0.9;
1.0-1.3; 1.4-1.8; > = 1.9.
Mg/dL: < = 79.7; 88.6-115.2;
124.0-159.5; > = 168.3
UC/NR: unclear, not reported; TG: Triglycerides; HTG, hypertriglyceridemia; MI, myocardial infarction; DM, diabetes, BP, blood pressure, HTN, hypertension
* It was unclear in most studies if enrolled patients did not have the outcomes pre-existent at baseline. In most studies, it was also unclear if patients were treated with drugs that can affect TG level (both of these
elements lower the observed strength of association)
Triglycerides Conversion from mg/dL to mmol/L: multiply by (x) 0.01129; from mmol/L to mg/dL: multiply by (x) 88.6
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8Odds ratio and 95% CI 
Odds  Lower  Upper  
ratio  limit  limit  p-Value 
Barrett-Connor, 1987 
All-cause mortality 
1.00 0.90 1.11  1.00 
Carlson,  1988  0.96 0.56 1.64  0.88 
Habib,  2006  0.45 0.34 0.59  0.00 
Haim,  1999  (men)  1.09 0.94 1.26  0.25 
Haim,  1999  (women)  1.10 0.80 1.51  0.56 
Schupf,  2005  1.01 0.79 1.29  0.94 
Sprecher,  2000  1.26 1.00 1.59  0.05 
Tanko,  2005  1.90 1.18 3.05  0.01 
Tsai,  2008  1.01 0.85 1.20  0.88 
Upmeier,  2009  1.03 0.73 1.46  0.86 
Weir,  2003  2.42 1.93 3.04  0.00 
1.10 0.90 1.36  0.35 
0.2  0.5  1  2  5  10 
Decreased risk with hypertriglyceridemia  Increased risk with hypertriglyceridemia
Meta Analysis 
Figure 2 Random effects meta-analysis (all-cause mortality).
Cardiovascular death 
Statistics for each study  Odds ratio and 95% CI 
Odds  Lower  Upper  
ratio  limit  limit  p-Value 
Barrett-Connor, 1987  1.00  0.90  1.11  1.00 
Bass, 1993  6.92  3.40  14.08  0.00 
Chan, 2005  2.97  1.00  8.80  0.05 
Eberly, 2003  1.26  0.99  1.61  0.06 
Ellingsen, 2003  1.43  0.88  2.31  0.15 
Mazza, 2005  2.45  1.48  4.05  0.00 
Tanko, 2005  3.10  1.40  6.86  0.01 
Tsai, 2008  1.08  0.78  1.50  0.64 
Weir, 2003  1.95  1.44  2.63  0.00 
1.80 1.31 2.49  0.00 
0.5  1  2  5  10 
Decreased risk with hypertriglyceridemia  Increased risk with hypertriglyceridemia
Meta Analysis 
Figure 3 Random effects meta-analysis (cardiovascular death).
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Page 14 of 18The overall confidence in the estimated magnitude of
associations is low [10]considering the described metho-
dological limitations in evaluating the association with
cardiovascular events; and imprecision (small number of
events) in evaluating the association with pancreatitis.
The strengths of this study stems from the compre-
hensive literature search that spans across multiple data-
bases and duplicate appraisal and study selection. Our
results are consistent with previous evidence synthesis
reports about the association of hypertriglyceridemia
with cardiovascular events. We estimated increased odds
by 37% (odds ratio of 1.37). Hokanson and Austin [3]
estimated adjusted relative risks of 1.14 (95% Cl 1.05-
1.28) in men and 1.37 (95% Cl 1.13-1.66) in women.
Sarwar et al. [2] reported odds ratio of 1.73 in prospec-
tive cohort studies published prior to 2006. A systematic
review by Labreuche et al. [49] demonstrated that base-
line triglyceride levels in randomized trials is associated
with increased stroke risk (adjusted RR, 1.05 per 10-mg/
dL (0.1 mmol/L) increase; 95% CI, 1.03-1.07). To our
knowledge, this is the first systematic review that sought
to identify controlled studies evaluating the association
with pancreatitis.
Implications
The associations demonstrated between hypertriglyceri-
demia and cardiovascular risk should not necessarily
translate into a recommendation for treatment. It is
plausible that the benefits of lowering triglycerides do
not merely depend on how much the level is lowered,
but rather on how it is lowered (i.e., lifestyle interven-
tions vs. pharmacological therapy). Therefore, rando-
mized trials of the different approaches with patient-
important outcomes [50] used as primary endpoints are
needed for making policy and clinical decisions.
Several systematic reviews and meta-analyses [49,51-54]
have summarized the evidence from randomized trials of
fibrate therapy and demonstrated that fibrate therapy
reduced the risk of vascular events (RR 0.75, 95% CI 0.65
to 0.86) in patients with high triglyceride levels or athero-
genic dyslipidemia (low HDL cholesterol combined with
high triglyceride level) although all-cause mortality and
non cardiovascular mortality were both significantly
increased in clofibrate trials. Meta-analyses [55,56] of nia-
cin therapy demonstrate significant reduction in the risk
of major coronary events (25% reduction in relative odds;
95% CI 13, 35), stroke (26%; 95% CI 8, 41) and any
Odds ratio and 95% CI  Odds   Lower   Upper  
ratio  limit  limit  p-Value 
Acarturk,  2004  1.62 1.02 2.58  0.04 
Bansal,  2007  1.11 0.92 1.34  0.28 
Bonaventure,  2010  1.49 1.24 1.79  0.00 
Chester,  1995  2.30 1.68 3.16  0.00 
Czernichow,  2007  1.30 1.21 1.39  0.00 
Drexel,  2005  1.17 1.00 1.37  0.05 
Eberly,  2003  1.64 1.20 2.24  0.00 
Egger,  1999  1.12 0.88 1.43  0.36 
Goldberg, 2009  7.96  2.65  23.94  0.00 
Hoogeveen,  2001  1.07 0.98 1.16  0.12 
Lamarche,  1995  3.10 1.54 6.25  0.00 
Lu,  2003  1.42 1.11 1.81  0.00 
Mora,  2008  1.47 1.00 2.16  0.05 
Rubins,  1999  1.12 0.86 1.46  0.39 
Samuelsson,  1994  1.21 1.03 1.43  0.02 
Valdivielso, 2009  4.41  1.59  12.22  0.00 
1.37 1.23 1.53  0.00 
0.5  1  2  5  10 
Decreased risk with hypertriglyceridemia  Increased risk with hypertriglyceridemia
Meta Analysis 
Cardiovascular events 
Figure 4 Random effects meta-analysis (cardiac events).
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Page 15 of 18Odds ratio and 95% CI 
Odds  Lower  Upper  
ratio  limit  limit  p-Value 
Gaziano, 1997  2.70  1.36  5.35  0.00 
Jonsdottir, 2002 (men)  1.21  1.08  1.36  0.00 
Jonsdottir, 2002 (women)  1.40  1.15  1.70  0.00 
Lu, 2003  2.04  1.12  3.70  0.02 
Malone, 2009  1.17  1.08  1.27  0.00 
Noda, 2010  1.46  0.89  2.39  0.13 
1.31 1.15 1.49  0.00 
0.5  1  2  5  10 
Meta Analysis 
Myocardial Infarction 
Decreased risk with hypertriglyceridemia  Increased risk with hypertriglyceridemia
Figure 5 Random effects meta-analysis (myocardial infarction).
Table 3 Subgroup analysis
Subgroup No.
studies
OR LL UL P-effect
Size
P-
interaction
Mortality
Men 3 1.03 0.95 1.12 0.49 0.04
Women 3 1.55 1.05 2.27 0.03
adequate adjustment 9 1.09 0.83 1.43 0.55 0.54
inadequate adjustment 3 1.22 0.94 1.59 0.14
General population 10 1.09 0.87 1.37 0.46 0.49
Diabetes 2 1.37 0.75 2.50 0.31
Cardiovascular death
Men 3 1.14 0.92 1.40 0.23 0.00
Women 2 4.73 2.15 10.37 0.00
adequate adjustment 5 1.88 1.12 3.15 0.02 0.84
inadequate adjustment 4 1.76 1.18 2.62 0.01
General population 8 1.75 1.26 2.43 0.00 0.36
Diabetes 1 2.97 1.00 8.80 0.05
Cardiovascular events
Men 6 1.29 1.13 1.47 0.00 0.67
Women 2 1.21 0.94 1.57 0.14
adequate adjustment 12 1.39 1.23 1.58 0.00 0.91
inadequate adjustment 4 1.37 1.01 1.84 0.04
General population 15 1.37 1.22 1.54 0.00 0.81
Diabetes 1 1.42 1.11 1.81 0.00
Myocardial infarction
Men 2 1.22 1.09 1.37 0.00 0.24
Women 1 1.40 1.15 1.70 0.00
adequate adjustment 3 1.72 0.98 3.01 0.06 0.29
inadequate adjustment 3 1.26 1.15 1.39 0.00
General population 5 1.27 1.13 1.44 0.00 0.13
Diabetes 1 2.04 1.12 3.70 0.02
*Only feasible analyses are shown
Murad et al. BMC Endocrine Disorders 2012, 12:2
http://www.biomedcentral.com/1472-6823/12/2
Page 16 of 18cardiovascular events (27%; 95% CI 15, 37). However, con-
temporary trials in the statin era have failed to substantiate
these findings with fenofibrate among patients with dia-
betes [57] and with niacin in high risk patients [58]. Also,
to our knowledge, there are no trials assessing the value of
triglyceride lowering to reduce the risk of pancreatitis.
Thus, lifestyle changes should remain the mainstay of
therapy. Treatment of the underlying metabolic disorder
(e.g., insulin resistance) should also be an essential and
first step in the management plan of hypertriglyceridemia.
Conclusions
The current evidence suggests that hypertriglyceridemia is
associated with increased risk of cardiovascular death, MI,
cardiovascular events, and acute pancreatitis. The strength
of inference is limited by the unexplained inconsistency of
results and high risk of confounding and publication bias.
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